'Modest support' for PFS as OS surrogate in HER2-positive metastatic breast cancer
The Medical News,
By Shreeya Nanda Progression-free survival (PFS) only moderately correlates with overall survival (OS) at the individual and…
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer †
Overview of attention for article published in Annals of Oncology, March 2016
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (93rd percentile)
-
High Attention Score compared to outputs of the same age and source (86th percentile)
Readers on
- mendeley
- 76 Mendeley